Mucosal immune responses to meningococcal C polysaccharide–protein conjugate in mice

Mucosal delivery of vaccines represents an attractive approach because this is a region of first contact point for inhaled antigens. We have obtained a meningococcal group C polysaccharide–tetanus toxoid conjugate (MGCP-TT) and evaluated it for intranasal route in mice. The conjugate was obtained by...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 24; pp. S72 - S73
Main Authors Cuello, Maribel, Cabrera, Osmir, del Campo, Judith M., Parajón, Elina, Sotolongo, Franklin, Camaraza, Maria A., Arnet, Aida, Suárez, Magaly, Pérez, Oliver
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.04.2006
Subjects
Conjugate vaccine
Meningococcal group C
N. meningitidis
Nasal
Neisseria meningitidis
Meningococcal group C
Nasal
N. meningitidis
Conjugate vaccine
Online AccessGet full text

Cover

More Information
Summary:Mucosal delivery of vaccines represents an attractive approach because this is a region of first contact point for inhaled antigens. We have obtained a meningococcal group C polysaccharide–tetanus toxoid conjugate (MGCP-TT) and evaluated it for intranasal route in mice. The conjugate was obtained by a developed method in our laboratory. The specific IgA in saliva and specific IgA and IgG in serum were measured by ELISA methods and bactericidal antibodies in sera against a meningococcal group C strain were measured. The conjugated elicited a significant increase in anti-MGCP salivary IgA and serum IgG and bactericidal antibodies concentrations, while specific serum IgA was not observed. These results indicated that after conjugation, there was a change in the responses for MGCP from thymus-independent to thymus-dependent and that it was effective by intranasal route.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2005.01.129